Publications from our projects and of relevance
- Blache et al. Potential solutions for manufacture of CAR T cells in cancer immunotherapy
- Sayed et al. Efficient correction of oncogenic KRAS and TP53 mutations through CRISPR base editing
- Ding et al. DNA methylation–independent long-term epigenetic silencing with dCRISPR/Cas9 fusion proteins
- Subramanian et al. Long-term culture-expanded alveolar macrophages restore their full epigenetic identity after transfer in vivo
- Rutella et al. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia
- Kunadt et al. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
- Lansing et al. Correction of a Factor VIII genomic inversion with designer-recombinases
- Teipel et al. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR-T-cell treatment
- Seif et al. CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models
- Lock et al. Automated, scaled, transposon-based production of CAR T cells
- Platzbecker et al. Luspatercept in patients with non-transfusion dependent β-thalassaemia
- García-Guerrero et al. ATRA works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T-cells
- Nguyen-Le et al. Nanosensors in clinical development of CAR-T cell immunotherapy
- Peng et al. ROR1-targeting switchable CAR-T cells for cancer therapy
- Röhnert et al. Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
- Nagler et al. Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis
- Hayden et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
- Locke et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
- Saini et al. Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies
- Taube et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
- Garcia-Manero at al. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
- Weidner et al. Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
- Bethge et al. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany
- Stubbins et al. Inflammation and myeloid malignancy: Quenching the flame
- Hartmann et al. Compartment-specific mutational landscape of clonal hematopoiesis
- Campos Ramos et al. The era of in vivo T cell engineering
- von Bonin et al. Clonal hematopoiesis and its emerging effects on cellular therapies
- Jayavelu et al. The proteogenomic subtypes of acute myeloid leukemia
- Eckardt et al. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
- Merz et al. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma
- Mank et al. Efficacy and Safety of Enteral Recombinant Human Insulin in Preterm Infants: A Randomized Clinical Trial
- Hernández-Malmierca et al. Antigen presentation safeguards the integrity of the hematopoietic stem cell pool
- Braun et al. Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in T-cell Prolymphocytic Leukemia
- Xu et al. A Self-Assembled Matrix System for Cell-Bioengineering Applications in Different Dimensions, Scales, and Geometries
- Guedan et al. Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?
- Kubasch et al. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO
- Donnadieu et al. Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
- Hoersten et al. Pairing of single mutations yields obligate Cre-type site-specific recombinases
- Récher et al. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
- Eckardt et al. Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears
- Medler et al. CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism
- Komrokji et al. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
- Lückemeier et al. Global k off -rates of polyclonal T-cell populations merge subclonal avidities and predict functionality
- Božić et al. Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns
- Zanotti et al. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
- Damaschin et al. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
- Nguyen-Le et al. Nanosensors in clinical development of CAR-T cell immunotherapy
